Dyslipidemia in high cardiovascular risk patients. Initial results from the REMEXDIS-IMSS study
DOI:
https://doi.org/10.5281/zenodo.10998739Keywords:
Cholesterol, Hypolipidemic Agents, Myocardial Infarction, LDLAbstract
Background: There is no national registry on dyslipidemia and low-density lipoprotein cholesterol (LDL-c) goals by risk groups for atherosclerotic cardiovascular disease (ACVD) focused on beneficiaries of the Mexican Institute for Social Security (IMSS).
Objective: To determine the frequency of dyslipidemia, LDL-c goals and patients in treatment from high and very high-risk groups of ACVD.
Material and methods: Multicenter, cross-sectional, descriptive study. This article derives from the Mexican Registry of Dyslipidemias in patients at high-risk and very high-risk of atherosclerotic cardiovascular disease (REMEXDIS-IMSS Project). Patients with high-risk and very high-risk criteria for ACVD were included.
Results: From July 2022 to March 2023, 6000 patients were included (3289 patients in the high-risk group and 2771 in the very high-risk group). The frequency of dyslipidemia was observed in 49% of the cohort. The very high-risk group presented a higher percentage of dyslipidemia in 66.8%, acute myocardial infarction in 81.0% and angina pectoris in 21.9%. The use of statins was higher in this group (93.3%) and the LDL-c goal was achieved in 72.9% (p < 0.0001).
Conclusions: The frequency of dyslipidemia is found in almost half of the population. The very high-risk group had a higher frequency of dyslipidemia, better use of statins for indication of secondary prevention, and a greater number of patients with LDL-c goals compared to the high-risk group.
Downloads
References
Lindstrom M, DeCleene N, Dorsey H, et al. Global burden of cardiovascular diseases and risks collaboration, 1990-2021. J Am Coll Cardiol 2022; 80: 2372-425. doi: 10.1016/j.jacc.2022.11.001.
Adhikary D, Barman S, Ranjan R, et al. A systematic review of major cardiovascular risk factors: A growing global health concern. Cureus. 2022; 24: e30119. doi: 10.7759/cureus.30119.
Lechner K, McKenzie AL, Kränkel N, et al. High-risk atherosclerosis and metabolic phenotype: The roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation. Metab Syndr Relat Disord. 2020; 18: 176-85. doi: 10.1089/met.2019.0115.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80:1366-418. doi: 10.1016/j.jacc.2022.07.006.
The HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217-27. doi: 10.1056/nejmoa1706444.
Murphy S, Pedersen T, Gaciong Z, et al. Effect of the PCSK9 inhibitor evolucumab on total cardiovascular events in patients with cardiovascular disease: A prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4:613-9. doi: 10.1001/jamacardio.2019.0886.
D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 2008;117:743-53. doi: 10.1161/circulationaha.107.699579.
Mu X, Wu A, Hu H, et al. Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus. Front Endocrinol. 2022;13:1077632. doi: 10.3389/fendo.2022.1077632.
Klisić A. Cardiovascular risk assessed by Reynolds risk score in relation to waist circumference in apparently healthy middle-aged population in Montenegro. Acta Clin Croat. 2018;57:22-30. doi: 10.20471/acc.2018.57.01.03.
Monroy R. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. doi: 10.1016/s0195-668x(03)00114-3.
Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88. doi: 10.1093/eurheartj/ehz455.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73:e285-350. doi: 10.1016/j.jacc.2018.11.003.
Mendoza-Romo MA, Montes-Acuña JF, Zavala-Cruz GG, et al. Efecto de DiabetIMSS sobre el riesgo cardiovascular, la tensión arterial y el colesterol-HDL en pacientes con síndrome metabólico. Rev Med Inst Mex Seguro Soc. 2017;55(1):32-39. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/1133/1752.
Roque D, Ferreira J, Monteiro S, et al. Understanding a woman’s heart: Lessons from 14177 women with acute coronary syndrome. Rev Port Cardiol. 2020;39:57-72. doi: 10.1016/j.repc.2020.03.002.
Borrayo G, Rosas M, Ramírez E, et al. STEMI and NSTEMI: Real-world study in Mexico (RENASCA). Arch Med Res. 2018;49:609-19. doi: 10.1016/j.arcmed.2019.01.005.
Mora-Solorzano L, Gutierrez-Diaz GI, Gudiño-Amezcua DA et al. Características clínicas de pacientes con infarto agudo de miocardio tratados con trombólisis en rgencias. Rev Med Inst Mex Seguro Soc. 2020;58:100-7. doi: 10.24875/rmimss.m20000006.
De los Ríos M, Leiva J, Rodríguez H, et al. Risk stratification and lipid evaluation in Mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The Mexican registry of cardiovascular diseases (REMECAR group). Atheroscler Plus. 2022;50:32-9. doi: 10.1016/j.athplu.2022.08.002.
Nowak MM, Niemczyk M, Florczyk M, et al. Effect of statins on all-cause mortality in adults: A systematic review and meta-analysis of propensity score-matched studies. J Clin Med. 2022;11:5643. doi: 10.3390/jcm11195643.
Pintarić H. Management of hyperlipidemia in very high and extreme risk patients in Croatia: An observational study of treatment patterns and lipid control. Acta Clin Croat. 2020;59:641-9. doi: 10.20471/acc.2020.59.04.10.
Shaya FT, Sing K, Milam R. Lipid-lowering efficacy of ezetimibe in patients with atherosclerotic cardiovascular disease: A systematic review and meta-analyses. Am J Cardiovasc Drugs. 2020;20:239-48. doi: 10.1007/s40256-019-00379-9.
Orkaby A, Driver J, Ho YL, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020;324:68-78. doi: 10.1001/jama.2020.7848.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-107. doi: 10.1056/nejmoa1801174.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999-3058. doi: 10.1093/eurheartj/ehw272.
Guía ESC/EAS 2019 sobre el tratamiento de las dislipemias: modificación de los lípidos para reducir el riesgo cardiovascular. Rev Esp Cardiol. 2020;73:403.e1-403.e70. doi: 10.1016/j.recesp.2019.10.031.
De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135-146. doi: 10.1016/j.atherosclerosis.2019.03.014.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista Médica del Instituto Mexicano del Seguro Social
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
